Japan Second Committee On Drugs Approves IFN-Free Hepatitis Drug
This article was originally published in PharmAsia News
Executive Summary
Japan’s Second Committee On Drugs deliberated and accepted the approval of six drugs including Bristol Myers’s 60mg Dacluinza (daclatasvir hydrochloride) tablets and 100mg Sunbepra (asunaprevir) capsules, both for the treatment of serogroup 1 chronic hepatitis C or type C compensated cirrhosis patients untreatable with interferons.